Promoting Resilience in Adolescents and Young Adults with Sickle Cell Disease

This study is looking at ways to help adolescents and young adults (ages 8-25) with sickle cell disease (SCD) manage their illness and improve their well-being. It's testing a program called "Promoting Resilience in Stress Management" (PRISM) along with a "Collaborative Care Model." PRISM helps with stress management, setting goals, and positive thinking, and is delivered one-on-one by trained coaches. The Collaborative Care Model involves a team meeting weekly to review your needs and offer support. The main goal is to see if these approaches are practical and well-received by patients. Researchers will also explore if they can help reduce depression, anxiety, and pain. You may be able to join if you have SCD, receive care at DFCI/BCH, and have certain scores on anxiety or depression questionnaires. This study plans to enroll 25 participants, but its current status is unclear.

Study design
This is an interventional study that plans to enroll 25 participants. It is testing a behavioral intervention delivered through a collaborative care model.
What's involved
Sessions for the PRISM intervention are delivered every 1-2 weeks based on your preference. The interprofessional team will meet weekly to review survey scores and health needs.
Compensation
Not stated in the trial record.
Follow-up
The primary goal of the study is measured at 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06555939

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

Recruiting
NAAges 8–25InterventionalTreatment
Boston Children's Hospital
~25 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:Collaborative Care ModelPromoting Resilience in Stress Management

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enrollment rate (feasibility)
Measured over 3-months
Sickle Cell Disease
1 sites across 1 states
Massachusetts1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged ≥ 8 and ≤ 25 years of age at baseline
Diagnosed with Sickle Cell Disease (HbSS, HbSC, HbS-Beta Thalassemia, and other related hemoglobinopathies)
Receiving Medical Care at the DFCI/BCH Blood Disorders Center.
Scored \> 9 on Patient Health Questionnaire 9-item (PHQ-9) or Generalized Anxiety Disorder (GAD)
Able to speak English or Spanish language (for PRISM sessions)
Able to read English or Spanish language (for completion of surveys)
Cognitively able to participate in PRISM sessions and complete written questionnaires and surveys, as judged by the site investigator
Willing and able to adhere to the study visit schedule and other protocol requirements
  • Enrollment rate (feasibility)3-months

    feasibility assessed by \>50% enrollment rate